Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of 5-aminolevulinic acid (Ameluz)

CHMP recommended license extensions for treatment of mild to moderate actinic keratosis and of field cancerization in adults; and treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment.

European Medicines Agency